In another study by Baker et al.,31 in which various positivity thresholds were tested, by using training and validation sets of both NSCLC and non-medullary thyroid cancers, the authors proposed for Abbott’s Vysis RET break-apart probe a three-tiered scoring system aiming at maximizing sensitivity given the small number of RET fusion-positive cases. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.